A detailed history of Pro Share Advisors LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Pro Share Advisors LLC holds 11,796 shares of AUTL stock, worth $35,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,796
Previous 12,313 4.2%
Holding current value
$35,270
Previous $42,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.38 - $4.69 $1,747 - $2,424
-517 Reduced 4.2%
11,796 $42,000
Q2 2024

Aug 13, 2024

BUY
$3.33 - $5.68 $41,002 - $69,937
12,313 New
12,313 $42,000
Q4 2021

Feb 08, 2022

SELL
$5.1 - $7.0 $62,179 - $85,344
-12,192 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.32 - $7.37 $64,861 - $89,855
12,192 New
12,192 $80,000
Q1 2019

May 15, 2019

SELL
$24.38 - $34.71 $149,229 - $212,459
-6,121 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$24.21 - $48.01 $148,189 - $293,869
6,121 New
6,121 $201,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.